Noah Medical

1.1 Identity and commercial position

Noah Medical describes itself as a medical robotics company focused on earlier diagnosis and treatment, with Galaxy as its robotic-assisted bronchoscopy platform. Independent trade reporting corroborates the product category and reports FDA clearance in March 2023. The commercial architecture combines a reusable capital platform with single-use bronchoscopes and accessories, suggesting equipment revenue plus recurring consumables, although neither pricing nor revenue mix is public. Galaxy II launched in August 2026 with software supporting HD-DT and CBCT imaging. A company-issued September 2026 release said the platform had exceeded 16,000 U.S. procedures and entered commercial use in Hong Kong; those scale figures remain company claims rather than audited customer or revenue metrics. Public descriptions also use both San Carlos and San Jose for the company, so the current headquarters and legal domicile require confirmation.[CO001, CO002, CO003, CO004, CO005, CO012, CO014]

1.2 Leadership and governance

Founder and CEO Jian Zhang is the only clearly identified corporate executive across the retained evidence. Independent reporting links his experience to Intuitive Surgical, Auris Health, and Robotphoenix, providing direct founder-market fit in surgical and industrial robotics. Noah's own materials say the broader team has experience from several established medical-robotics companies, but they do not provide a current executive roster. The company newsroom also lists Dr. Krish Bhadra as Chief Pulmonary Advisor, while product materials and reporting document his clinical use of Galaxy. This supports clinical-adviser coverage but does not resolve board composition, executive succession, control rights, or whether key technical and commercial responsibilities are distributed beyond Zhang. Governance and key-person concentration therefore remain material diligence items.[CO009, CO010, CO011, CO013]

1.3 Financing and stakeholders

The strongest financing evidence is an April 2023 $150 million Series B, independently reported by Global Corporate Venturing and also named in Noah's newsroom index. SoftBank Vision Fund and Prosperity7 Ventures co-led the round, with Hillhouse Capital, Sequoia China, and a broader syndicate participating. This establishes a substantial institutional funding event but not total capital raised, current cash, valuation, ownership percentages, board seats, preferences, secondary transactions, or debt. No retained source substantiates the previously reported 2025 financing or a current valuation, so those figures are excluded rather than rolled forward. The cap table and investor-rights package must be obtained directly before assessing control, dilution, or financing runway.[CO007, CO008]

1.4 Milestones and risk signals

The evidence shows a rapid path from March 2023 clearance to commercial deployment, 500 U.S. procedures by January 2024, later clinical readouts, and a 2026 software and geographic expansion cycle. That progression is meaningful operational evidence, but procedure counts are not equivalent to installed systems, customers, revenue, or utilization. The timeline also includes an April 2025 FDA warning letter reported by MassDevice. The report described current-good-manufacturing-practice, CAPA, and medical-device-reporting concerns and said the agency was arranging a follow-up visit. No retained 2026 source establishes final resolution, so regulatory remediation should be treated as open. Reported 2025 studies showed encouraging diagnostic-yield results, but company-sponsored announcements and trade coverage do not substitute for a full review of study design, adverse events, and commercial cohort quality.[CO002, CO003, CO004, CO005, CO006, CO007, CO015, CO016]

1.5 Exhibits

2.1 Market boundary and status-quo substitutes

Noah Medical's addressable market is not "lung cancer" in the broad sense, and it is not the upstream LDCT screening market by itself. The product sits in the downstream diagnostic workflow for suspicious lung lesions, especially peripheral lesions that are hard to biopsy accurately with conventional bronchoscopy or with fragmented navigation-plus-imaging setups. The relevant spend therefore includes robotic bronchoscopy capital and software, disposable bronchoscopes and accessories, and the workflow value of integrated imaging; it excludes screening scans themselves, unrelated oncology treatment, and broader thoracic surgery budgets. The top of funnel is still constrained by screening penetration: CDC says only about 18% of recommended U.S. adults have been screened, so market growth depends on both more screened patients and better diagnostic conversion after a lesion is found.[CM001, CM002, CM003, CM004, CM015]

2.2 Buyer, user, and adoption path

The user is the interventional pulmonology or bronchoscopy team, but the economic buyer is the hospital lung nodule program or service-line owner that has to justify space, capital, staff time, and throughput. The assigned pool consistently frames adoption as a community-hospital expansion story rather than a pure academic-center story: smaller footprint, single-use scopes, and integrated imaging are positioned as ways to reduce reprocessing burden, crowded-room friction, and separate CBCT investment. That matters because community sites run tighter room-utilization and staffing economics than flagship centers. Coverage also matters in the adoption path: CDC says most insurance plans and Medicare help pay for recommended screening, but abnormal follow-up testing can still create patient cost-sharing and hospital workflow friction that slows conversion from clinical interest to scaled program volume.[CM007, CM011, CM012, CM013, CM014]

2.3 Evidence-constrained sizing, drivers, and constraints

Public evidence in this pool is stronger on why adoption can happen than on how large the revenue pool is. The best sizing proxies are workflow and performance lenses: CDC's screening funnel, Noah's claim that peripheral lesions are hard to reach, a 31-patient imaging study with 96.7% diagnostic yield, a 70-case community-hospital series with reported financial sustainability, and repeated 90%-yield routine-use references. Together they support demand drivers such as earlier diagnosis, physician control of imaging, lower radiation in routine cases, and endoscopy-suite deployment. They also preserve real constraints: unresolved regulatory overhang, still-missing public TAM/SAM/SOM math, and no audited ROI or reimbursement durability by customer segment. That means the market can be described as promising and expanding, but not yet underwritten precisely from public evidence alone.[CM005, CM006, CM008, CM009, CM010, CM014]

2.4 Exhibits

3.1 Direct peer pressure is concentrated in Ion; most other alternatives are workflow substitutes

The retained evidence does not show a broad set of scaled robotic bronchoscopy rivals; instead, it shows a two-track landscape. Noah has moved from FDA clearance in 2023 to 5,000 U.S. procedures by March 2025 and a company-claimed base of more than 16,000 U.S. procedures by September 2026, which is enough to prove real commercial traction but not enough to match the incumbent's public scale. Intuitive's own Q1 2026 disclosures put Ion at 43,000 quarterly procedures, 52 quarterly placements, and an installed base that MarketChameleon summarized at 1,041 systems, so the direct peer with the clearest commercial weight is Ion rather than a fragmented field of similar startups. That matters because the other alternatives visible in this pool look more like ways to solve the same clinical job without buying Noah, not like another documented scaled robotic vendor. Noah's own 2023 and 2026 materials repeatedly frame the benchmark as current bronchoscopy technologies, embedded versus external imaging, and workflow burden inside crowded bronch suites. In other words, the buyer is not only comparing Noah against one robot. It is also comparing Noah against staying with reusable-scope workflows, keeping cone-beam CT as a confirmation layer, or internally assembling a hybrid room workflow that preserves the current operating model.[CP001, CP005, CP006, CP007, CP008, CP009, CP014]

3.2 Noah competes on integrated imaging, disposable workflow, and room footprint rather than raw scale

Noah's strongest documented differentiation is workflow design. Noah's own product materials say Galaxy is the only robotic bronchoscopy platform with a single-use disposable bronchoscope, and Fierce's clearance coverage repeated that this was a first-of-kind attribute in robotic bronchoscopy. The same Noah materials position Galaxy as an integrated imaging stack rather than a navigation-only platform: the original 2023 release described integrated tomosynthesis plus augmented fluoroscopy, the 2026 MATCH II coverage reported 96.7% diagnostic yield with 96.7% DT-to-CBCT concordance, and the 2026 Galaxy II launch described HD-DT as the low-radiation default with CBCT available when the case requires escalation. That combination makes Noah's best competitive narrative less about claiming the broadest ecosystem and more about reducing handoffs between navigation, confirmation, cleaning, and room logistics. Those features also define the substitute set. Reusable bronchoscopy workflows remain viable because they avoid new robotic capital purchases, but the retained evidence also ties them to reprocessing burden and infection-control tradeoffs that the FDA has publicly flagged. External-CBCT workflows can still act as a high-confidence confirmation benchmark, yet Noah is explicitly trying to absorb that benchmark into one platform so the hospital does not have to assemble a larger hybrid setup for every case. The practical implication is that Noah can win where procedure efficiency, room footprint, and reprocessing burden matter enough to outweigh the safety of staying with established workflows.[CP002, CP003, CP004, CP011, CP012, CP014, CP015]

3.3 Durability depends on whether Noah's workflow wedge can outrun incumbent scale and trust risk

The moat is real but not obviously durable yet. Intuitive's public 2026 evidence shows a disclosed 1,041-system Ion installed base, 43,000 quarterly Ion procedures, continued system placements, and an $8.0 billion cash-and-investments position, which gives the incumbent room to keep funding training, service, digital features, and additional lung-workflow integration such as ROSE and endobronchial ultrasound. Noah does not disclose a comparable installed-base count in the retained evidence. The available evidence therefore supports a resource and disclosed-scale advantage for Intuitive, not a precise installed-base ratio. That does not disprove Noah's product wedge; it does mean Noah is competing against a better-capitalized incumbent that can respond through bundle depth and customer-support breadth rather than through a point-for-point copy of Noah's single-use positioning. Noah also has a trust and execution handicap visible in the retained 2026 evidence. MassDevice linked the Galaxy II launch to an April 2025 FDA warning letter and said the agency was still working to schedule a follow-up visit. At the same time, public pricing remains opaque for both Noah and Ion in this source set, which means the market is easier to understand on technical workflow and scale than on realized economic switching thresholds. For diligence, that leaves the competitive verdict as "credible wedge, but not yet durable proof": Noah appears differentiated enough to win on workflow design, yet the strongest public evidence still suggests that the competitive center of gravity sits with Intuitive's scale and Noah's ability to defend trust while converting that workflow edge into sticky adoption.[CP007, CP008, CP009, CP010, CP013, CP016]

3.4 Exhibits

4.1 Revenue architecture is plausible but not disclosed

Galaxy combines a robotic bronchoscopy platform, a single-use bronchoscope and accessories, and commercially launched Galaxy II software. That product structure creates three plausible monetization layers: system access, per-procedure consumables, and software or service value. The retained evidence, however, does not establish that Noah charges separately for each layer, whether systems are sold or leased, how software is entitled, or whether service and training carry recurring fees. Galaxy II is marketed as adding capability without added capital, which may strengthen the installed system's value but does not prove incremental software revenue. The revenue bridge is therefore a diligence framework rather than a forecast, and no public product activity should be converted into revenue without contract terms and realized pricing.[CI001, CI002, CI004, CI006, CI007, CI014, CI015, CI016]

4.2 Procedure traction is not a revenue disclosure

Noah reported 5,000 U.S. Galaxy procedures by March 24, 2025, evidence that the system had moved beyond initial launch and generated procedure activity. It does not disclose the number of installed systems, active accounts, procedures per active system, units consumed per case, recognized revenue, or collection timing. The current public surfaces also provide no list price, realized average selling price, lease rate, minimum commitment, discount schedule, or contract duration for the platform, disposables, or Galaxy II. Consequently, the procedure milestone can support a commercial-activity conclusion but cannot support ARR, revenue, utilization, customer-count, or payback calculations. Underwriting requires contract-level reconciliation from placements to active systems, procedures, disposable shipments, invoicing, and cash collection.[CI003, CI007, CI015]

4.3 Consumables may recur, while cost and quality exposure remain unknown

Noah's single-use bronchoscope and accessories create a logical per-procedure consumption mechanism, and the company says disposability removes reprocessing burden and supports faster turnaround. Those claims do not reveal the disposable bill of materials, transfer price, scrap rate, warranty reserve, logistics cost, or hospital-level cost comparison. Intuitive's preliminary 2025 results illustrate why placements and procedures must be separated: its Ion placements declined while Ion procedures grew, and its broader instruments-and-accessories revenue tracked procedure growth. This is a business-model benchmark, not a Noah estimate. Separately, MassDevice's account of FDA warning-letter deficiencies raises possible remediation, service, warranty, and adoption costs, but no retained source quantifies their financial impact.[CI004, CI005, CI009, CI010, CI011, CI012, CI013]

4.4 Capital adequacy cannot be underwritten from funding headlines

The retained current sources disclose no Noah revenue, ARR, gross margin, cash balance, burn rate, runway, debt, lease obligations, working-capital requirement, or capital-expenditure plan. Financing raised historically would not equal cash available today, so it is not a substitute for a current balance sheet and monthly cash bridge. The product model also creates potentially material cash demands before revenue quality is known: system manufacturing and deployment, disposable inventory, field service, software development, regulatory remediation, and customer support. The financial verdict is therefore evidence of commercial activity but insufficient evidence of durable revenue quality, margin expansion, or financing independence. Investment underwriting should wait for audited statements, monthly operating metrics, debt documents, and downside runway scenarios tied to deployment and utilization.[CI003, CI008, CI009, CI016]

4.5 Exhibits

5.1 Product definition in the bronchoscopy workflow

Noah Medical sells Galaxy as an all-in-one robotic-assisted bronchoscopy platform for physicians trying to reach, localize, and biopsy peripheral lung lesions in a standard bronchoscopy workflow rather than through a multi-vendor imaging stack. The official 2023 clearance materials position Galaxy for bronchoscopic visualization of and access to patient airways, while Noah's own product pages emphasize a disposable bronchoscope, compact single-cart footprint, and setup/turnover benefits for support staff. A customer-site description from Meadville Medical Center reinforces that the product is being presented to hospitals as an image-integrated workflow tool, not just a robotic arm or navigation accessory.[CE001, CE005, CE006]

5.2 Architecture and operating model

The public architecture evidence is more specific than typical medtech marketing copy. Noah and a 2026 independent real-world study both describe a stack that starts with thin-cut pre-procedure CT upload and 3D planning, moves through EMN-guided navigation, and then uses TiLT+ digital tomosynthesis through a standard C-arm to confirm tool position relative to the lesion. Noah's 2026 Galaxy II launch extends that same installed platform with dual-mode HD-DT and optional CBCT workflow selection plus lesion-focused imaging, which suggests Noah is iterating the imaging/control layer on top of one hardware base rather than launching a second product family. What remains unclear from the reviewed sources is interoperability: the pool does not expose APIs, PACS/EHR integration detail, or service-SLA documentation.[CE002, CE003, CE004, CE009, CE013]

5.3 Clinical maturity and deployment evidence

Noah now has enough public evidence to argue Galaxy is past prototype stage, but not enough to call the platform fully de-risked. The strongest 2026 commercialization signal in this pool is the first commercial procedure in Asia at Prince of Wales Hospital, alongside Noah's claim that the U.S. installed base has surpassed 16,000 procedures. Clinical evidence is directionally encouraging but still uneven: the independent Journal of Thoracic Disease study covers 91 patients and 94 nodules in first-year academic use with a 68% strict diagnostic yield and meaningful complication rates, while the same paper notes that prior Galaxy data came from more controlled FRONTIER and MATCH 2 settings, including the 96.7% MATCH 2 yield. That pattern supports real product maturity, but also shows that operator learning curve and site conditions still matter.[CE007, CE008, CE011, CE012]

5.4 Differentiation, quality controls, and technical risk

The most supportable product differentiation is operational rather than algorithmic: Galaxy combines real-time imaging confirmation with a single-use bronchoscope, compact room footprint, and software-controlled modality switching, which can matter in crowded bronchoscopy suites and for hospitals trying to reduce reprocessing burden. The main technical counterweight is quality-system risk. MassDevice's 2026 reporting ties the Galaxy II launch to an unresolved 2025 FDA warning letter that cited manufacturing and CAPA failures, reportability lapses, and device-complaint handling concerns. For diligence, that means Noah's product edge may be genuine, but underwriting still depends on verifying whether manufacturing, field reliability, and post-market controls have caught up to the commercial push.[CE005, CE006, CE009, CE010, CE013]

5.5 Exhibits

6.1 Customer segments and buying surface

The evidenced deployment unit is a hospital bronchoscopy program rather than an individual consumer. FDA materials define physicians as the operators, while commercial examples name interventional pulmonologists and thoracic surgeons at U.S. and Hong Kong hospitals. Noah's customer-facing workflow proposition combines integrated imaging, a compact cart, and a single-use bronchoscope; the company argues that disposability reduces reprocessing burden and supports room turnover. A practitioner-authored discussion of robotic bronchoscopy adds a separate community-hospital lens: integrated imaging can avoid extra imaging equipment and may permit endoscopy-suite deployment. These sources identify users and institutional settings, but not the procurement committee, reimbursement payer, purchase-versus-lease model, or budget owner. Accordingly, the segmentation is useful for go-to-market diligence but incomplete for revenue modeling.[CU002, CU008, CU009, CU010, CU011]

6.2 Adoption trajectory

The public milestones show a credible transition from clearance to use. FDA cleared Galaxy on March 1, 2023, and MassDevice reported that the first U.S. commercial use followed in May 2023. By January 2024, Noah announced its 500th U.S. use, performed at CHI Memorial. In September 2026, a paid company release reported more than 16,000 U.S. procedures and the first commercial procedure in Asia at Prince of Wales Hospital. The sequence indicates rising cumulative procedure volume and geographic expansion, but it is not a customer-growth series: no source supplies installed-system counts, active-site counts, procedures per system, or the same-period denominator. The latest volume should therefore remain a company claim rather than an independently verified utilization metric.[CU001, CU003, CU004, CU005, CU006, CU007]

6.3 Named deployment and outcome proof

CHI Memorial is the strongest independently reported production reference in the pool: MassDevice identifies it as Tennessee's first adopting hospital and the site of the 500th U.S. case. Prince of Wales Hospital is a fresher geographic reference, although its commercial milestone and procedure totals come from a syndicated company release. Clinical evidence is supportive but should not be conflated with a customer roster. Healio reported a 31-patient MATCH 2 study with high tool-in-lesion and diagnostic-yield results, while also reporting one pneumothorax requiring tube thoracostomy and admission. FDA clearance materials add simulated-use validation by representative trained users, not proof of paid deployment. This hierarchy separates production use, company-announced expansion, clinical evaluation, and pre-commercial validation.[CU004, CU005, CU006, CU012, CU013, CU014, CU015]

6.4 Durability, expansion, and concentration

Procedure accumulation is the clearest public expansion signal, and the Hong Kong launch demonstrates that a clinical relationship can precede commercial integration. However, procedure totals alone do not establish durable customer economics. The retained evidence contains no NRR, GRR, churn, renewal rate, contract duration, reorder rate, installed-base utilization, customer count, or revenue concentration disclosure. It also does not show whether the more than 16,000 U.S. procedures are broadly distributed or concentrated in a small number of high-volume sites. Underwriting should therefore treat retention and concentration as material data-room gaps. The most decision-useful request is a site-level cohort showing installation date, monthly procedures, disposable reorder cadence, contract status, and revenue, together with top-five and top-ten customer shares.[CU006, CU007, CU011, CU016]

6.5 Exhibits

7.1 Ranked underwriting frame

The public risk stack is led by one issue that can still break the thesis: quality-system remediation after the FDA warning letter. That issue matters more than ordinary medtech execution noise because it combines manufacturing process control, complaint handling, and MDR timing, and it remained open enough in August 2026 for MassDevice to report that a follow-up visit was still being scheduled. The next tier of risk is economic rather than technical: Noah markets meaningful workflow advantages and has reported growing procedure counts, but independent reimbursement guides still show advanced bronchoscopy economics depend on multi-code documentation and payer-specific billing logic rather than a simple, uniform procedure payment. The third tier is dependency risk. Much of the strongest adoption proof still comes from company-controlled milestones and a relatively small set of named hospitals and physician champions, so scale outside flagship sites needs to be demonstrated rather than assumed.[CR004, CR006, CR007, CR010, CR011, CR013, CR016]

7.2 Regulatory, quality, and legal exposure

Noah has a credible regulatory base in that Galaxy received FDA clearance in March 2023 for bronchoscopic visualization of and access to patient airways, but that clearance is only the starting point for risk analysis, not the end state. The same product family later became the subject of a warning-letter episode that independent coverage described in unusually specific terms: FDA reportedly found Galaxy bronchoscopes and accessories "adulterated" from a current-good-manufacturing-practice perspective, and the article also described CAPA and MDR timing deficiencies. That makes regulatory exposure operational as much as legal: new software and imaging layers can improve clinical utility, yet every additional workflow claim or release cadence increases the importance of disciplined design control, complaint handling, and post-market reporting. The assigned pool also shows some patent depth, but it does not surface freedom-to-operate opinions, litigation dockets, or privacy/security contracting evidence, so legal diligence remains incomplete even if there is no public problem statement in the retained evidence.[CR001, CR003, CR004, CR005, CR006, CR014]

7.3 Operating model, reimbursement, and financial fragility

Noah's operating model carries a classic medtech tradeoff. The single-use bronchoscope architecture and compact workflow are meaningful mitigants for contamination, reprocessing burden, and room turnover, but those same choices can shift risk toward disposable supply availability, gross-margin discipline, and hospital contribution-margin math. The public reimbursement guides retained for this refresh make that point indirectly: billing for bronchoscopy is heavily bundled, navigation is an add-on, and the highest value advanced-bronchoscopy economics come from a well-documented code mix, not just the base scope. That means Noah still has to prove that workflow efficiency plus diagnostic performance reliably offsets capital, disposable, and revenue-cycle friction. The public record is weakest on the financial backstop underneath that story because the assigned pool surfaces product milestones and funding history but does not disclose revenue, margin, burn, cash, or runway.[CR002, CR008, CR009, CR010, CR011, CR012, CR016]

7.4 Dependency map, kill criteria, and diligence asks

The dependency pattern is visible even in this constrained source set. Noah's evidence of traction is real but concentrated: company-controlled milestones cite 5,000 U.S. procedures by March 2025 and more than 16,000 U.S. procedures by September 2026, while named champions and sites such as Long Island Jewish Medical Center, City of Hope Cancer Center Atlanta, and Prince of Wales Hospital anchor much of the narrative. MTEC's profile also suggests a training- and study-support layer that likely helps adoption but can slow scale if deployments remain services-heavy. The practical kill criteria are therefore monitorable. A repeat or escalated FDA quality finding, a failure to show positive site-level reimbursement contribution margin, or evidence that expansion remains stuck in a small number of reference centers would each materially weaken the investment case. Before underwriting new money, diligence should request direct quality-remediation evidence, economics by procedure setting, and a current board-level view of cash runway and supply resilience.[CR007, CR010, CR011, CR013, CR015, CR016]

7.5 Exhibits

8.1 Recommendation and entry discipline

The assigned valuation evidence supports a cautious posture rather than an invest-at-any-price conclusion. Noah still shows meaningful commercial momentum: independent reporting ties the business to a 2023 oversubscribed $150 million Series B, and a 2026 company-issued release says the platform has now supported more than 16,000 procedures in the United States while also reaching its first commercial case in Asia. But those positives do not solve the core underwriting problem: the current public evidence set still lacks a current priced round, revenue disclosure, gross margin detail, burn, runway, and preference-stack terms. Without those inputs, the disciplined call is research-more, with medium confidence and a high risk rating, and any engagement should be conditioned on primary financing and operating-data review rather than on narrative momentum alone.[CV001, CV003, CV010, CV011, CV015]

8.2 Thesis and anti-thesis

The pro-underwrite case rests on two observable facts. First, Noah appears to have built a differentiated robotic bronchoscopy product: multiple sources describe embedded imaging, TiLT+ workflow, and a single-use disposable bronchoscope, while June 2024 clinical coverage reported 100% successful navigation and 100% tool-in-lesion accuracy in the 18-patient FRONTIER study. Second, commercialization is no longer theoretical, because the company says the platform has crossed 16,000 U.S. procedures and begun commercial use in Asia. The anti-thesis is equally material. A 2026 MassDevice report says the FDA warning letter from April 2025 was still awaiting follow-up, and the same report cites CAPA and MDR-process deficiencies; older independent coverage also continued to reference Auris trade-secret litigation. That combination caps conviction until revenue quality and regulatory cleanup are verified directly.[CV002, CV003, CV004, CV007, CV008, CV009]

8.3 Scenarios and comparable anchors

The cleanest external anchor in the assigned pool is not a Noah valuation multiple but a public strategic benchmark: Intuitive reported about $10.06 billion of 2025 revenue and 195 Ion endoluminal system placements, illustrating how much larger the category leader already is than Noah’s disclosed operating proof. That makes Noah’s 2023 private round only a stale financing reference, not a current value floor. The scenario framework therefore has to stay qualitative. A bull case requires Noah to translate reported procedure volume, Galaxy II product updates, and geographic expansion into verified revenue scale without new regulatory drag. A base case supports only disciplined follow-up diligence. A bear case includes flat or down-round risk, or investor-protective terms, if remediation or utilization disappoints.[CV001, CV003, CV005, CV006, CV012, CV013, CV014]

8.4 Exit readiness and final diligence asks

Public evidence does not yet support a hold-period target, return hurdle, or exit multiple, because the missing variables are exactly the ones that drive medtech pricing: installed-base utilization, disposable pull-through, gross margin by capital versus consumables, cash burn, runway, and the liquidation-preference stack. The next diligence step is therefore not model refinement but source quality escalation. Management should provide current financing documents, cohort-level commercial KPIs, and direct evidence of FDA follow-up status. The thesis should be considered broken if a new financing is required before those metrics are shared, if warning-letter remediation extends without clear closure, or if commercialization momentum fails to convert into verifiable recurring economics.[CV007, CV008, CV010, CV011, CV012, CV013, CV014, CV015]

8.5 Exhibits